The Latest in FDA Evaluations and Research

FDA News

Top Stories

With the proliferation of applications across the enterprise - LAN, WAN, and data center – the need to optimize applications across wide area networks is greater than ever, and performance becomes the new vanguard in network and service management. As the borderless enterprise takes hold, with distributed workers and branches collaborating over video, mobile, and other multimedia applications, enterprises are looking for service providers that can help improve the user experience with quality of service (QoS) guarantees. This means service providers need to have the ability to deliver end-to-end performance assurance and management of applications using application performance management (APM), optimization and acceleration solutions like Cisco Wide Area Application Service (WAAS). Enterprises today are grappling with increasing complexity in their applications env... (more)

Medipattern Builds International Presence in China

TORONTO, ONTARIO -- (MARKET WIRE) -- 02/12/07 -- Attention: Business/Financial Editors: The Medipattern Corporation (TSX VENTURE: MKI), an award-winning developer of computer-aided diagnosis (CAD) solutions for medical imaging, is pleased to announce the signing of a distribution agreement with Beijing Eastwide Medical, Ltd., headquartered in Beijing, PRC. This agreement is the result of Medipattern's recent decision to establish a global distribution network for its products. Beijing Eastwide has an extensive sales network, with more than 20 offices in various provinces throughout China. The company specializes in the sale of women's health products to breast centres and hospitals. Their products include mammography systems, ultrasound systems, and biopsy systems. Ms. Zhao Xue-zhen, General Manager of Beijing Eastwide Medical, Ltd., said, "Breast cancer is a seriou... (more)

Syneron's LipoLite(TM) Minimally Invasive Laser-Assisted Lypolysis Receives FDA Clearance

YOKNEAM, ISRAEL -- (MARKET WIRE) -- 05/01/08 -- Syneron(TM) Medical Ltd. (NASDAQ: ELOS), an innovator in the development, marketing and sales of elos(TM) combined-energy medical aesthetic devices, today announced the introduction of LipoLite(TM), Syneron's new device for laser-assisted lipolysis. The LipoLite device this week received U.S. Food and Drug Administration (FDA) clearance for laser-assisted lipolysis and additional dermatological procedures. For patients, LipoLite is both a minimally invasive alternative and a complement to traditional liposuction fat-removing procedures. The procedure requires only local anesthetic and is designed to provide patients lasting results with little downtime and a high level of safety. For physicians, the small, compact LipoLite system is comfortable to use, upgradeable to support future applications and fits easily on tabl... (more)

Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization

RICHMOND, British Columbia, June 5 /PRNewswire/ -- Edge Health Solutions, innovators of medical and dental practice management software developed specifically to leverage the power of Mac OS X, announces the release of edgeMD 2.0(TM) and edgeDMS 2.0(TM). This breakthrough practice management software enables physicians, dentists, and other medical professionals to manage their practice, providing paperless clinical charting and delivers the only integrated FDA-approved diagnostic imaging solution running on the Mac. It also includes value-added features from TreAura, making edgeMD 2.0(TM) and edgeDMS 2.0(TM) truly an all-in-one practice management solution. Since Apple, Inc. is known for bringing revolutionary, intuitive, and affordable technology to market, Edge Health Solutions has developed edgeMD 2.0(TM) and edgeDMS 2.0(TM) exclusively for use on the Mac. edgeMD ... (more)

Pathway Medical Technologies Receives FDA Clearance for Jetstream(TM) Pathway PV(TM) Atherectomy System

KIRKLAND, WA -- (Marketwire) -- 09/05/08 -- Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral arterial disease (PAD), today announced that the U.S. Food & Drug Administration (FDA) has given the company clearance to market Jetstream(TM), a peripheral atherectomy catheter designed for use in the treatment of PAD in the lower limbs. The clearance marks the company's second 510(k) clearance and the first device on the market capable of treating an entire spectrum of disease found in the PAD patient, including hard and soft plaque, calcium, thrombus and fibrotic lesions with consistent clinical results. Pathway Medical Technologies President and CEO Tom Clement commented, "The market introduction of Jetstream(TM) represents a major business milestone for our organization and a dramatic new treatment option for the endovascular c... (more)

Health This Week with Don Baillargeon, 4/23

LOS ANGELES, CA -- (Marketwire) -- 04/23/09 -- Health This Week with Donald Baillargeon is an internationally syndicated television program about the many ways people are exploring to live better, healthier and longer lives. Free information about the featured guests can be requested by sending an email to [email protected] The television program can also be viewed online immediately at Featured guests on this week's program include: Imaging3, Inc. (OTCBB: IMGG) CEO Dean Janes talked about the company's Dominion Medical Imaging device, which is portable, uses standard electric power and displays 3D images in real time. The device is awaiting FDA approval. Nick Delgado, Ph.D., of Health Wellness Studios, Inc., said that patients could spend three to five days in Newport Beach, CA and undergo his stem cell treatment program. Clinical P... (more)

Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting

Collaboration with Noted Neurologists to Plan Next Clinical Studies OMAHA, Neb. and HOUSTON, May 11 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM), announced the clinical introduction of the NuroPro(R) AD and NuroPro(R) PD tests for Alzheimer's and Parkinson's disease at the 2009 American Academy of Neurology meeting in Seattle, WA. The NuroPro tests help clinicians distinguish patients with Alzheimer's and Parkinson's diseases from "normal" individuals and patients with other neurological disorders. The tests, developed by Power3, are a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability a patient has neurodegenerative disease. This information will help physicians make earlier diagnoses and recommend appropriate follow-up and tr... (more)

FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia

Once-Daily SAMSCA Increases Serum Sodium Levels Through Increase in Free Water Clearance TOKYO and PRINCETON, N.J., May 21 /PRNewswire/ -- Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) announced today that the U.S. Food and Drug Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the only oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia (serum sodium less than 125 mEq/L, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic hormone (SIADH). Patients requiring urgent treatment to raise serum sodium to prevent or to treat serious neurological deficits should not be tr... (more)

Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development

SUNNYVALE, California, May 28 /PRNewswire/ -- Results from a clinical study published today in the New England Journal of Medicine reveal that ablative therapy using the HALO system (BARRX Medical, Inc.) is highly effective for complete eradication of a pre-cancerous condition of the esophagus called Barrett's esophagus afflicting more than 3.3 million Americans. Additionally, ablative therapy using the HALO system reduced the risk of progression to cancer in the highest risk cohort studied (compared to control) from 19.0% to 2.4%. The study entitled "Radiofrequency Ablation in Barrett's Esophagus with Dysplasia" is authored by lead investigator Nicholas J. Shaheen, M.D., Associate Professor of Medicine and Epidemiology, The University of North Carolina in Chapel Hill. "This is a well-designed trial conducted in a rigorous manner at 19 expert U.S. centers, each ha... (more)

Transoma Medical Receives FDA Marketing Clearance for Exclusive Capability Providing Immediate Access to Critical ECGs on Mobile Handheld Device

Transoma Medical, Inc., manufacturer of Sleuth® and Sleuth AT™, the only wireless and automated implantable cardiac monitoring (ICM) systems has received FDA 510(k) marketing clearance for its new Data Review feature on Sleuth AT. The Data Review feature allows any clinician to easily access up to 99 events stored on the patient’s Personal Diagnostic Manager (PDM). The PDM is a handheld device that retrieves and stores ECG data from the implanted device prior to automatic transmission to the 24/7 monitoring center. Each stored ECG strip is labeled with the time and date of the cardiac event making it easier for clinicians to correlate symptoms with rhythms. “Instant access to a patient’s ECG data on the mobile handheld device is a clinically valuable tool in urgent situations, such as when the patient presents in the emergency room,” said Dr. Asim Yunus, an elect... (more)

PROTOMED SA Chooses HyperWorks to Simulate Implantable Medical Devices

TROY, Michigan and MARSEILLE, France, July 30 /PRNewswire/ -- Altair Engineering, Inc., a leading global provider of simulation technology and engineering services that empower client innovation and decision-making, and PROTOMED SA announced today that PROTOMED SA has chosen Altair Engineering's computer-aided engineering (CAE) software suite, HyperWorks, to enhance its numerical simulation capabilities. PROTOMED SA continues to expand its medical device R&D services by choosing Altair as its official computational software partner. The products of the software suite, especially its RADIOSS solver for implicit analysis tasks will be used within service projects of PROTOMED and to develop new and innovative implantable medical devices. PROTOMED engineers use CAE to predict physical responses of biological systems to known load conditions and will use HyperWorks to mo... (more)